MKNK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL173840	0.50	17/20
SCHEMBL162573	0.52	16/20
SCHEMBL31554	0.63	15/20
SCHEMBL146532	0.51	13/20
SCHEMBL6026	0.55	12/20
SCHEMBL31555	0.62	11/20
SCHEMBL167082	0.58	11/20
SCHEMBL317029	0.51	11/20
SCHEMBL204513	0.51	9/20
SCHEMBL205583	0.51	9/20
SCHEMBL323980	0.50	9/20
SCHEMBL206263	0.71	8/20
SCHEMBL133437	0.58	8/20
SCHEMBL6027	0.58	8/20
SCHEMBL233227	0.53	8/20
SCHEMBL205967	0.53	8/20
SCHEMBL196216	0.52	8/20
SCHEMBL208351	1.00	7/20
SCHEMBL148200	0.57	6/20
SCHEMBL181902	0.44	6/20

Clinical trials — most relevant to MKNK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer	PHASE2	COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia	PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome	PHASE1	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MKNK1 binder may also engage these)

Protein	Name	Similarity
O08605	—	1.000	O08605 →
Q4G050	—	1.000	Q4G050 →
Q5U2N4	—	1.000	Q5U2N4 →
Q66I46	—	1.000	Q66I46 →
Q66JF3	—	0.999	Q66JF3 →
Q6P431	—	0.997	Q6P431 →
Q7TNL3	—	0.996	Q7TNL3 →
MKNK2	MAP kinase-interacting serine/threonine-protein kinase 2	0.996	landscape →
Q39183	—	0.996	Q39183 →
Q58D94	—	0.995	Q58D94 →
Q17QV9	—	0.995	Q17QV9 →
Q9FG74	—	0.995	Q9FG74 →
Q9SUA3	—	0.995	Q9SUA3 →
Q3ULB5	—	0.995	Q3ULB5 →
A2YBX5	—	0.995	A2YBX5 →
Q8CDB0	—	0.995	Q8CDB0 →
Q9ZUZ2	—	0.994	Q9ZUZ2 →
Q63553	—	0.993	Q63553 →
RPS6KB1	Ribosomal protein S6 kinase beta-1	0.993	landscape →
Q8BSK8	—	0.993	Q8BSK8 →
Q7TNL4	—	0.993	Q7TNL4 →
Q6TJY3	—	0.993	Q6TJY3 →
Q5R8Z4	—	0.993	Q5R8Z4 →
STK32C	Serine/threonine-protein kinase 32C	0.993	landscape →
Q8N2I9	—	0.992	Q8N2I9 →
O80673	—	0.992	O80673 →
Q2KJ16	—	0.992	Q2KJ16 →
Q39491	—	0.992	Q39491 →
D3YXS5	—	0.991	D3YXS5 →
Q91VB2	—	0.991	Q91VB2 →